Document Detail

Optimization of treatment in Turner's syndrome.
MedLine Citation:
PMID:  15134303     Owner:  NLM     Status:  MEDLINE    
We discuss treatment for short stature and hypogonadism in patients with Turner's syndrome, using recombinant human growth hormone (GH) and estrogen. We discuss the starting dose of GH, age at start of treatment, and association with oxandrolone or low dose estrogen therapy before 12 years old. We provide recommendations for optimization of therapy for best final height and induction of puberty with estrogen therapy. Our experience in the Children's Endocrinology Clinic in "La Paz" University Hospital, Madrid, is that 83% of our patients need estrogen therapy and only 17% had spontaneous menarche. The average age for puberty induction was 12.2 years, and the average duration of estrogen treatment was 2.1 years. The average final height obtained using GH treatment was 151.3 cm with a gain related to predicted height of 6.8 cm.
R Gracia Bouthelier; A Oliver Iguacel; Isabel Gonzalez Casado; A Alcalde de Alvaré
Related Documents :
16449073 - Growth in pre-pubertal children with myelomeningocele (mmc) on growth hormone (gh): the...
17731523 - Magma generation on mars: amounts, rates, and comparisons with earth, moon, and venus.
21904143 - Long-term results of fibrin glue treatment for cryptogenic perianal fistulas: a multice...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of pediatric endocrinology & metabolism : JPEM     Volume:  17 Suppl 3     ISSN:  0334-018X     ISO Abbreviation:  J. Pediatr. Endocrinol. Metab.     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-05-11     Completed Date:  2005-05-03     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9508900     Medline TA:  J Pediatr Endocrinol Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  427-34     Citation Subset:  IM    
Endocrinología Pediátrica, Hospital Infantil La Paz, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Growth Hormone / therapeutic use
Oxandrolone / therapeutic use
Recombinant Proteins / therapeutic use
Treatment Outcome
Turner Syndrome / drug therapy*,  physiopathology
Reg. No./Substance:
0/Recombinant Proteins; 53-39-4/Oxandrolone; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Childhood-onset congenital adrenal hyperplasia: long-term outcome and optimization of therapy.
Next Document:  Fetal growth regulation and intrauterine growth retardation.